2、现货黄金涨0.48%，报3325.02美元/盎司；COMEX黄金期货持平，报3346.70美元/盎司；COMEX白 银期货涨2.12%，报36.91美元/盎司。国际油价走强，美油主力合约收涨1.24%，报65.38美元/桶；布伦 特原油主力合约涨0.96%，报67.11美元/桶。欧洲三大股指收盘小幅下跌，德国DAX指数跌0.54%报 24174.32点，法国CAC40指数跌0.17%报7791.47点，英国富时100指数跌0.06%报8832.28点。 3、据新华社报道，中办、国办联合印发的《关于进一步保障和改善民生 着力解决群众急难愁盼的意 见》6月9日对外公布。意见从增强社会保障公平性、提高基本公共服务均衡性、扩大基础民生服务普惠 性、提升多样化社会服务可及性等方面作出部署，支持引导有条件的地方将生育保险生育津贴按程序直 接发放给参保人、合理提高最低工资标准、稳步推进灵活就业人员参加住房公积金制度、加大保障性住 房供给、新建改扩建1000所以上优质普通高中等多项举措。 （二）行业掘金 1、6月9日，工信部、民政部发布开展智能养老服务机器人结对攻关与场景应用试点工作的通知，试点 期为2025—2027年 ...

Core Viewpoint - The company has approved the use of idle fundraising for cash management, allowing investment in safe, liquid principal-protected products up to a maximum of RMB 1.5 billion [2][11]. Group 1: Cash Management Overview - The company plans to use idle funds from its non-public stock issuance to invest in principal-protected financial products, enhancing the efficiency and returns of the raised funds while ensuring no impact on ongoing projects [4][9]. - The cash management will involve a maximum of RMB 800 million in a structured deposit product from Hangzhou Bank, with a term of 364 days [6][10]. Group 2: Financial Product Redemption - The company redeemed a structured deposit product from Hangzhou Bank worth RMB 50 million, receiving the principal and a return of RMB 585,900 on June 6, 2025 [3]. Group 3: Financial Situation and Impact - As of March 31, 2025, the company's cash reserves were RMB 1,874.59 million, with the cash management investment representing 4.27% of total cash, indicating minimal impact on financial health [11]. - The use of idle funds for cash management is expected to improve fund utilization efficiency and generate returns for shareholders without affecting the company's operational projects [11].

Group 1: HPV Vaccine Market Overview - The HPV vaccine market in China grew from 940 million yuan in 2017 to 13.56 billion yuan in 2020, with a compound annual growth rate (CAGR) of 143.43% [1] - The global HPV vaccine market is expected to achieve a CAGR of 20.04% from 2020 to 2025, potentially reaching 16.8 billion USD by 2031 [2] Group 2: Policy and Market Drivers - The Chinese government is promoting inclusive development and prioritizing children's welfare, which includes enhancing HPV vaccination efforts among eligible girls [1] - The demand for HPV vaccines is anticipated to accelerate due to policy support and the rapid growth of domestic vaccine companies [2] Group 3: Company Developments - Wantai Biological Pharmacy's subsidiary, Xiamen Wantai Canghai, has received approval from the National Medical Products Administration for its nine-valent HPV vaccine, making it the first in China and the second globally [3] - Watson Bio's subsidiary, Shanghai Zerun, is advancing its phase III clinical trials for a nine-valent HPV vaccine, currently in the data analysis and clinical research report writing phase [3]

证券代码：603392 证券简称：万泰生物 公告编号：2025-034 北京万泰生物药业股份有限公司 关于使用部分闲置募集资金进行现金管理 到期赎回并继续进行现金管理的公告 （一）现金管理目的 鉴于公司募投项目均有较长的实施周期，为提高募集资金的使用效率和资金 效益，公司在确保不影响募集资金投资项目建设和募集资金使用的情况下，使用 部分闲置募集资金投资保本型理财产品，有利于提高募集资金的使用效率，增加 公司收益，保证股东利益最大化。 （二）资金来源 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 履行的审议程序：北京万泰生物药业股份有限公司（以下简称"公司"） 于2025年1月14日召开第六届董事会第六次会议、第六届监事会第六次会议，审 议通过了《关于使用部分闲置募集资金进行现金管理的议案》，同意公司使用最 高额度不超过人民币15亿元（含）的暂时闲置非公开发行股票募集资金适时投资 安全性高、流动性好的保本型产品，单项产品期限最长不超过12个月。该额度自 公司董事会审议通过之日起12个月内有效，可由公司及全资子公 ...

Investment Rating - Investment Rating: Positive [2] Core Insights - The pharmaceutical and biotechnology industry index increased by 3.36%, ranking 6th among 31 primary industries, outperforming the CSI 300 index, which decreased by 0.21% [5][17] - The valuation of the pharmaceutical and biotechnology industry as of June 6, 2025, is 28.24x (TTM, excluding negative values), up from 27.60x in the previous period, indicating an upward trend but still below the average [5][23] - Notable sub-industry performance includes chemical preparations and other biological products, with increases of 5.77% and 4.68% respectively, while offline pharmacies saw a decline of 1.15% [5][17] Industry Review - The report highlights three major investment opportunities: 1) Companies with dual-antibody/multi-antibody technology platforms that have differentiated target design capabilities and clinical advancement efficiency are likely to attract international giants [9] 2) Areas with unmet clinical needs, such as advanced liver cancer and non-small cell lung cancer, are promising for dual-antibody therapy development [9] 3) Potential license-out candidates, as domestic innovative pharmaceutical companies continue to engage in global collaborations [9] Important Industry News - CDE launched the "Star Plan" to encourage the development of pediatric anti-cancer drugs, addressing significant unmet clinical needs in this area [7][32] - Alcon's dry eye medication "Tryptyr" received FDA approval, marking it as the first of its kind globally [39] - Hansoh Pharmaceutical's third-generation EGFR-TKI "Amivantamab" was approved in the UK for first-line treatment of NSCLC, becoming the first domestically developed EGFR-TKI approved overseas [42] - BMS and BioNTech entered a collaboration for the dual-antibody candidate BNT327, with an upfront payment of $1.5 billion and potential milestone payments of $7.6 billion [51] Company Dynamics - Stone Pharmaceutical is negotiating three potential deals totaling $5 billion, involving several products including EGFR ADCs [49] - BMS's "Rotecip" was approved for treating lower-risk myelodysplastic syndromes, marking a significant innovation in this therapeutic area [45] - AbbVie’s JAK inhibitor "Upadacitinib" was approved for treating giant cell arteritis, becoming the first approved treatment for this condition in China [48]

Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical and biotechnology industry, but it indicates a positive outlook on the innovation drug sector, particularly regarding the international expansion of domestic innovative drugs [3][4]. Core Insights - The report highlights the continuous rise in the enthusiasm for innovative drugs going overseas, with significant collaborations such as the $9 billion partnership between Bristol-Myers Squibb and BioNTech for the development of a PD-L1/VEGF dual antibody [3][4]. - It notes that the domestic innovative drug pipeline is becoming increasingly competitive on a global scale, with a long-term positive outlook for the internationalization of innovative drugs [3][4]. - The report also discusses the recent peak of COVID-19 cases in China, with a positivity rate of 23.8% reported at the end of May, indicating a need for continued monitoring [3][4]. Market Weekly Review - The pharmaceutical and biotechnology sector rose by 1.13% from June 3 to June 6, underperforming compared to the Wind All A index, which increased by 1.61% [9][10]. - Among sub-sectors, raw materials and blood products both saw a rise of 2.89%, while in vitro diagnostics increased by 2% [10]. - Notable stock performances included Yiming Pharmaceutical with a 33.1% increase, while *ST Longjin experienced a significant decline of 36.3% [12]. Industry News and Key Company Announcements - Significant events include the presentation of clinical data for IBI363 by Innovent Biologics at the ASCO conference, showing promising efficacy in treating advanced non-small cell lung cancer [12][13]. - Stone Pharmaceutical received approval for its adenosylcobalamin capsules, expanding its product line in the blood and nervous system treatment areas [13]. - CanSino Biologics announced the approval of a new indication for its PD-1/CTLA-4 inhibitor, filling a gap in the treatment of cervical cancer in China [13]. - The report also mentions various other approvals and collaborations among companies, indicating a vibrant and active industry landscape [13][14].

Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical and biotechnology industry, but it indicates a positive outlook on the global competitiveness of domestic innovative drugs and the trend of innovative drugs going abroad [3][4]. Core Viewpoints - The innovative drug sector is experiencing a surge in overseas collaboration, highlighted by the partnership between Bristol-Myers Squibb and BioNTech to jointly develop a PD-L1/VEGF dual antibody with a total package worth $9 billion [3][4]. - The report notes that the recent ASCO conference showcased significant advancements in dual antibodies and ADCs, indicating a differentiated layout in early clinical stages for domestic innovative drugs [3][4]. - The report mentions a peak in the current COVID-19 wave, with a positivity rate of 23.8% reported at the end of May, which is higher than the entire year of 2024, although it has started to decline slightly [3][4]. Weekly Market Review - The pharmaceutical and biotechnology sector rose by 1.13% from June 3 to June 6, underperforming the Wind All A index, which increased by 1.61% [9][10]. - Among sub-sectors, raw materials and blood products both increased by 2.89%, while in vitro diagnostics rose by 2% [9][10]. - Notable stock performances included Yiming Pharmaceutical with a rise of 33.1%, Wanbangde at 32.6%, and Anglikang at 30.3%, while *ST Longjin fell by 36.3%, Huason Pharmaceutical by 12.4%, and Maipu Medical by 9.3% [12][10]. Industry News and Key Company Announcements - On June 4, Innovent Biologics reported promising Phase I clinical data for IBI363 in treating advanced non-small cell lung cancer at the ASCO annual meeting [12][13]. - On June 6, CSPC announced that its adenosylcobalamin capsules received drug registration approval from the National Medical Products Administration [13][14]. - On June 5, CanSino Biologics announced the approval of a new indication for its PD-1/CTLA-4 inhibitor in first-line treatment for cervical cancer [13][14]. - On June 2, Bristol-Myers Squibb and BioNTech announced a collaboration to develop the PD-L1/VEGF dual antibody BNT327, with a significant financial commitment involved [13][14].

Investment Rating - The report maintains a "Recommended" rating for the new materials industry [1]. Core Insights - The new materials sector is a crucial direction for the chemical industry, currently experiencing rapid growth in downstream demand. With policy support and technological breakthroughs, domestic new materials are expected to accelerate their long-term growth. The report emphasizes that "one generation of materials supports one generation of industry," highlighting the foundational role of the new materials industry in supporting other sectors [6]. Summary by Sections 1. New Materials Industry Dynamics 1.1 Electronic Information Sector - On June 6, SEMI reported that the global semiconductor equipment shipment value increased by 21% year-on-year in Q1 2025, reaching $32.05 billion. However, there was a 5% quarter-on-quarter decline due to typical seasonal patterns [8][24]. 1.2 Aerospace Sector - The report highlights key materials such as PI films, precision ceramics, and carbon fibers as areas of focus [11]. 1.3 New Energy Sector - The report emphasizes the importance of photovoltaic materials, lithium-ion batteries, proton exchange membranes, and hydrogen storage materials [13]. 1.4 Biotechnology Sector - The focus is on synthetic biology and scientific services, with a notable mention of China's potential to surpass the U.S. in biotechnology, particularly in drug development [15]. 1.5 Energy Conservation and Environmental Protection Sector - Key areas include adsorbent resins, membrane materials, and biodegradable plastics [16]. 2. Key Companies and Earnings Forecast - The report lists several key companies with their stock prices and earnings per share (EPS) forecasts for 2024, 2025E, and 2026E, along with their price-to-earnings (PE) ratios and investment ratings. For example, Ruihua Tai (688323.SH) has a stock price of 13.85 with an EPS forecast of 0.06 for 2025E, rated as "Increase Holding" [18]. 3. Industry Rating and Investment Strategy - The new materials sector is expected to benefit from the catalytic effects of downstream application sectors, gradually entering a prosperous cycle, thus maintaining a "Recommended" rating for the new materials industry [17].

Core Viewpoint - The approval of the first domestic nine-valent HPV vaccine, Xinkening®9, by Wantai Biological Pharmacy, marks a significant breakthrough in China's vaccine industry, challenging Merck's long-standing monopoly in the market [1][26]. Summary by Sections R&D and Product Value - Wantai Biological invested approximately 1 billion yuan over 18 years to develop Xinkening®9, achieving three major breakthroughs in vaccine technology [3][12]. - The vaccine utilizes an innovative E. coli expression system, resulting in higher immunogenicity, cost-effectiveness, and complete proprietary intellectual property [5][6]. Efficacy and Safety - Xinkening®9 can prevent infections from nine HPV types, covering over 90% of HPV-related infections, with proven efficacy and safety comparable to imported vaccines [6][7]. - A head-to-head study published in The Lancet confirmed that both domestic and imported vaccines had a 100% seroconversion rate for neutralizing antibodies [7]. Administration and Accessibility - The vaccine offers flexible dosing schedules: a two-dose regimen for females aged 9-17 and a three-dose regimen for those aged 18-45, making it more accessible compared to imported alternatives [11][12]. Pricing Strategy - The market is keenly awaiting the pricing strategy for Xinkening®9, with current expectations based on the pricing of the only other available nine-valent HPV vaccine, Gardasil®9, which costs around 1300 yuan per dose [13][14]. - Two main pricing strategies are anticipated: an aggressive pricing approach or a price set at 50%-70% of the imported vaccine's cost [14][15]. Market Potential and Growth - If priced between 700 to 800 yuan per dose, Xinkening®9 could balance commercial viability and social responsibility, addressing the significant gap in HPV vaccination rates in China [16][17]. - The global demand for HPV vaccines is robust, with projections estimating Xinkening®9 could reach sales of 22.8 billion yuan [23]. Future Expansion - Wantai Biological plans to expand into the male market and pursue international opportunities, leveraging its WHO pre-certification and existing market access in various countries [25]. - The approval of Xinkening®9 signifies a shift in China's vaccine industry from catching up to leading in core product development [26].

Core Viewpoint - Wantai Biological's 9-valent HPV vaccine has been approved in China, breaking the long-standing foreign monopoly and potentially reversing the company's declining revenue and profit trend [1][2]. Group 1: Company Performance - Wantai Biological's revenue and profit have been declining for several years, with reported revenues of 111.85 billion yuan in 2022, 55.11 billion yuan in 2023, and a projected 22.45 billion yuan in 2024. Net profits were 47.36 billion yuan, 12.48 billion yuan, and 1.06 billion yuan for the same years [4]. - In Q1 2025, the company continued to face challenges, with revenue of 4.01 billion yuan, a year-on-year decline of 46.76%, and a net loss of 0.53 billion yuan, a staggering decline of 141.98% [4]. Group 2: Market Dynamics - The approval of the 9-valent HPV vaccine is expected to boost Wantai's performance in 2025, as it can capture market share from Merck, which currently has the only competing product [8]. - The 9-valent HPV vaccine offers broader protection compared to the 2-valent version, which may enhance its market appeal [8]. Group 3: Competitive Landscape - The domestic HPV vaccine market has become increasingly competitive, with prices for the 2-valent HPV vaccine dropping significantly from 329 yuan to 86 yuan, leading to a substantial revenue decline for Wantai's vaccine segment [6][10]. - The market is expected to see more competitors entering with their own 9-valent HPV vaccines by 2026, which could lead to further price wars and impact Wantai's ability to maintain growth [15][16]. Group 4: Future Outlook - While the approval of the 9-valent HPV vaccine is a positive development for Wantai, the long-term growth outlook remains uncertain due to potential pricing pressures and increased competition from other domestic manufacturers [16].